Overview

A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments

Status:
Completed

Trial end date:
2001-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if the addition of capravirine to VIRACEPT (nelfinavir mesylate) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is an effective combination drug therapy for HIV patients who have failed a nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Agouron Pharmaceuticals

Treatments:

Capravirine
Nelfinavir
Reverse Transcriptase Inhibitors